Delivery Order SPE2DB25D7056-SPE2DB25FTNBA
- Not listed
- The Defense Logistics Agency awarded a $6,382.34 firm fixed price delivery order to AmerisourceBergen Drug Corp for Orilissa 150 mg tablets (quantity of 7 units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This non-set-aside contract represents a routine pharmaceutical procurement supporting federal medical supply needs. The award was made to AmerisourceBergen's corporate office, with performance occurring at the company's Conshohocken, Pennsylvania location. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Orilissa 150 mg tablets in quantities of 7 units, valued at $8,696.28. This firm fixed-price delivery order, which was not set-aside, was awarded on July 23, 2025, with an ultimate completion date of July 24, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order valued at $7,530.90 to AmerisourceBergen Drug Corp for Orilissa 150 mg tablets (7-count packages) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed price delivery order represents a non-competitive set-aside procurement and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, was selected to supply this specialized...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Orilissa 200 mg tablets (14-count packaging) with a ceiling value of $8,559.49 under a firm fixed-price contract. This non-set-aside award was competitively procured and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Orilissa 150 mg tablets. The $11,137.57 contract has a completion date of May 7, 2025 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,290.82, is for the delivery of Orilissa 150 mg tablets. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Orilissa 150 mg tablets. The contract has a ceiling value of $6,430.25 and a completion date of October 11, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which provides a comprehensive range of medical...
- This federal contract award, valued at $4,377.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Orilissa 150 mg tablets and has a completion date of December 10, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,790.09, is for the delivery of the medication Orilissa 150 mg tablets. The contract is a Firm Fixed Price Delivery Order without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,705.24, is for the supply of Orilissa 150 mg tablets. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth $999,999,999, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
- SPE2DB25D7056Indefinite Delivery Contract
- SPE2DB25D7056-SPE2DB25FTNBADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 4569155062, Orilissa 150 mg tablets (quantity 7), valued at $10,086.63 under a firm fixed price contract type. The award was made on August 20, 2025, with an ultimate completion date of August 21, 2025. No set-aside designation was used for this competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime indefinite delivery vehicle provides comprehensive pharmaceutical and medical supply support for military healthcare programs globally. AmerisourceBergen, a major pharmaceutical distributor and critical vendor for federal medical procurement, regularly fulfills diverse pharmaceutical needs including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.1k | 8/20/25 |